Fortress Biotech (NASDAQ:FBIOP – Get Free Report) is projected to announce its results before the market opens on Monday, November 16th. Analysts expect the company to post earnings of ($0.27) per share and revenue of $21.57 million for the quarter.
Fortress Biotech Stock Down 4.3%
Shares of FBIOP traded down $0.64 during mid-day trading on Friday, reaching $14.36. 10,355 shares of the stock traded hands, compared to its average volume of 19,123. Fortress Biotech has a 1 year low of $6.27 and a 1 year high of $21.43. The firm has a fifty day moving average price of $16.77 and a 200 day moving average price of $16.36.
About Fortress Biotech
Fortress Biotech, Inc. is a U.S.-based biopharmaceutical company that acquires, develops and commercializes prescription medicines. Its work spans areas including oncology, rare diseases, dermatology and other specialty markets. The company operates through a network of subsidiary businesses and uses partnerships and licensing arrangements to advance drug candidates and bring therapies to market. Its portfolio includes both development-stage programs and commercial products, with activities conducted primarily in the United States.
Further Reading
- Five stocks we like better than Fortress Biotech
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
